Biotech | September 21, 2021
HUTCHMED initiates a Japan bridging study to Support Surufatinib
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
Telemedicine services like SAATH and E-Sanjeevani add a meta-layer to the primary health sector, thus helping upgrade the entire health care system of India
Between 30-40 per cent of Covid-19 patients are either obese or diabetic
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
The panel is headed by DCGI Dr VG Somani with representatives from various state drug regulators and health ministry
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Subscribe To Our Newsletter & Stay Updated
